Comparison Study of Blood Glucose Monitoring Systems in People With Diabetes
Multicentre Performance Comparison Study of Blood Glucose Monitoring Systems in People With Diabetes Randomised to Multiple Devices
1 other identifier
observational
501
2 countries
3
Brief Summary
A Multicentre study comparing 5 different Self-Monitoring Of Blood Glucose (SMBG) system commercially available in Germany \& Holland.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2010
Shorter than P25 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 3, 2010
CompletedFirst Posted
Study publicly available on registry
November 4, 2010
CompletedStudy Start
First participant enrolled
December 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2011
CompletedMarch 23, 2026
March 1, 2026
3 months
November 3, 2010
March 19, 2026
Conditions
Keywords
Study Arms (1)
Diabetes
Patients with Type 1 or Type 2 diabetes requiring insulin.
Eligibility Criteria
Up to 480 subjects with type 1 or 2 diabetes mellitus
You may qualify if:
- Subjects diagnosed with type 1 or type 2 diabetes mellitus
- Age between 18 and 75 years.
- Patients with stable blood glucose in judgment of the investigator.
- Subjects receive intensive insulin therapy (Multiple Daily Injection defined as at least two insulin injections per day)
- Patients perform blood glucose self measurements on a routine basis
- Patients must have experience in self measurement blood glucose for at least 6 months.
You may not qualify if:
- Patients with unstable blood glucose in judgment of the investigator.
- Patient has been diagnosed with progressive / serious diseases that in judgment of the investigator preclude successful completion of the observational period.
- Lack of compliance or other justifications that, in the discretion of the investigator, precludes satisfactory participation in the study.
- Subject without legal capacity.
- Blood donation within the last 30 days.
- Known pregnancy.
- Subject has already participated in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Abbott Diabetes Carelead
- ikfe-CRO GmbHcollaborator
Study Sites (3)
Zentrum für Diabetes und Gefäßerkrankungen
Münster, 48145, Germany
Diabetes Zentrum Neuwied
Neuwied, 56564, Germany
Radboud University Nijmegen Centre
Nijmegen, 6500 HB, Netherlands
Related Publications (1)
Tack C, Pohlmeier H, Behnke T, Schmid V, Grenningloh M, Forst T, Pfutzner A. Accuracy evaluation of five blood glucose monitoring systems obtained from the pharmacy: a European multicenter study with 453 subjects. Diabetes Technol Ther. 2012 Apr;14(4):330-7. doi: 10.1089/dia.2011.0170. Epub 2011 Dec 16.
PMID: 22176154RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Joe Bugler
Abbott Diabetes Care
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 3, 2010
First Posted
November 4, 2010
Study Start
December 1, 2010
Primary Completion
March 1, 2011
Study Completion
March 1, 2011
Last Updated
March 23, 2026
Record last verified: 2026-03